Engflag

Aesim

Quick links to important sections

Aesim

Aesim_EN

Method of action: Antiflatulent, Antispasmodic, Carminative, Defoaming Agent, Drugs For Functional Gastrointestinal Disorders

Treatment option: Dyspepsia, Flatulence

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aesim

Quick Facts

Property Description
Active ingredient Simethicone (Activated Polydimethylsiloxane)
Form Oral Suspension, Tablets, Capsules, Emulsion
Pharmacological class Antiflatulent Agent
Common use Relief of gas, bloating, and pressure
Origin Synthetic, Silicone Compound

What Type of Medicine is Aesim (Simethicone)?

Aesim is a readily available, single-ingredient oral preparation classified as an Antiflatulent Agent, a category of medication clinically recognized for the safe, physical management of intestinal gas. Its active substance, Simethicone (chemically, Activated Polydimethylsiloxane), belongs to the silicone compound family. This substance is defined as a non-systemic, locally acting agent, which is a key distinguishing factor: it performs its intended function entirely within the gastrointestinal lumen and is not absorbed into the body’s bloodstream. Aesim is typically available in formulations suitable for the general population, including specific suspensions designed for infant use.

What is the General Purpose of an Antiflatulent Agent?

The primary therapeutic purpose of an Antiflatulent Agent like Aesim is the physical relief of discomfort caused by the accumulation of trapped gas, addressing common symptoms such as post-meal bloating, abdominal pressure, and flatulence. Simethicone achieves this by acting as a surface-active substance that reduces the surface tension of gas bubbles within the gut's contents. Pharmacological studies confirm that Simethicone helps by promoting the coalescence of numerous small, foamy gas pockets into larger bubbles. This physical mechanism simplifies the process of gas elimination via belching or flatulence, thus offering effective relief from pressure. Aesim is manufactured in multiple dosage forms, including concentrated oral suspensions and standard softgel capsules, ensuring suitability for various patient needs.

Regulatory References

  1. Simethicone - StatPearls - NCBI Bookshelf

What side effects are possible with Aesim?

Possible Side Effects and Safety Information

The official safety information for Aesim is organized to communicate the medicine’s risk profile by classifying documented adverse reactions and specifying limitations on its use.

Adverse Reactions are systematically presented by their observed frequency in clinical studies and grouped by the System-Organ-Class (SOC) they affect. This classification provides a quantifiable summary of the potential side effect profile.

Key Safety Categories

Category Description based on Regulatory Documentation
Frequency Classification Adverse reactions are listed according to standard frequency bands (e.g., Very Common, Common, Uncommon) based on incidence rates observed in clinical trials.
System-Organ-Classes Side effects are organized by the specific body systems involved, such as Blood and Lymphatic System Disorders, Nervous System Disorders, or Skin and Subcutaneous Tissue Disorders.
Serious Adverse Reactions Specific risks that are considered clinically significant and may lead to severe outcomes are highlighted in official documents, often requiring immediate attention.
Safety Restrictions (Contraindications) The official labeling defines mandatory limitations for use, outlining specific conditions or patient populations where the medicine must not be administered due to unacceptable risk.
Warnings and Precautions Situations or patient populations that require particular caution, monitoring, or risk minimization measures are formally identified in regulatory warnings.
Population-Specific Risks The safety data addresses differential risk profiles for specific patient groups, such as those with severe hepatic or renal impairment, where the drug’s use may be contraindicated or require special monitoring.

Regulatory authorities use these structured domains to establish the boundaries for the medicine’s safe use and ensure that prescribers and patients are informed of the known risks and required monitoring activities.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Aesim

Overdose scope

Documented overdose presentations:

  • No specific systemic signs or symptoms of overdose are documented in regulatory labeling.
  • Acute systemic toxicity is not expected following ingestion, even at high doses.

Physiological systems affected (as stated in label):

  • No physiological systems are documented to be systemically affected in overdose, as the active ingredient is not absorbed into the body’s bloodstream.

Dose-related or exposure-related factors (if applicable):

  • The only documented factor that triggers regulatory action is massive ingestion or accidental overdose.

Population-specific overdose notes (if applicable):

  • No population-specific increase in overdose severity (e.g., in children or the elderly) is explicitly stated in official labeling.

Emergency-response statements (as written in official documents):

  • Seek immediate medical attention or contact emergency services upon suspected massive overdose.
  • Calling a Poison Control Center is a standard officially recommended action.

When immediate medical help is required (label-derived phrasing only):

  • When a massive or accidental overdose is suspected.

Overdose classifications (high-level)

Severity classification (as defined in official documents):

  • Overdose is generally classified as resulting in no expected systemic toxicity.

Regulatory basis:

  • The overdose profile is based on the substance's inert, non-systemic pharmacological classification documented by government authorities.

Overdose-context constraints (as defined in official documents):

  • Management is limited to symptomatic and supportive treatment. No specific antidote is known or required.

Resulting overdose structure

Official overdose statements:

  • Overdose with Aesim is not expected to produce acute systemic toxicity, consistent with the fact that the active substance, Simethicone, is not absorbed.
  • No specific antidote is known or required for an overdose.
  • Despite the low anticipated systemic risk, immediate medical help must be sought following any suspected massive ingestion.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the overdose profile of Aesim by the absence of systemic toxicity and the lack of specific, documented systemic symptoms. This is directly linked to the drug’s non-systemic action. Regulators require that emergency medical help be sought immediately for massive ingestions, with official management limited to symptomatic and supportive care.

Therapeutic Uses of Aesim

Aesim belongs to the category of non-steroidal anti-inflammatory drugs (NSAIDs), which is relevant in contexts involving heightened systemic burden. The primary therapeutic domain of this class is applied across areas where additional symptomatic support is needed, specifically for managing pain, inflammation, and addressing symptoms related to systemic imbalance.

The medication is commonly used across conditions presenting with acute episodes. It is relevant for easing symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. This includes long-term conditions where functional stability becomes affected, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It may also assist with managing symptoms related to temporary issues like headaches, muscle aches, sprains, and menstrual cramps.

NSAIDs are often used during phases when symptoms become more noticeable. Ultimately, Aesim contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. The medication helps maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress.

Quick Fact: Supports the management of symptoms related to physical discomfort

Eligibility and Restrictions for Use

Aesim, as a complex biologic medication, is typically reserved for patients with specific immune-mediated diseases that have not responded adequately to conventional therapies. It is generally prescribed and managed by specialists experienced in these conditions and biological agents.

Potential Users of Aesim

  • Patients diagnosed with the approved indications, which may include conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, or ulcerative colitis.
  • Individuals who have undergone necessary pre-screening for latent infections (e.g., tuberculosis, hepatitis B/C) and other contraindications.

Individuals Who Cannot Use Aesim

Contraindications for Aesim are similar to those for other immunosuppressive biologics and are critical for patient safety. Patients with the following conditions are generally not eligible to receive Aesim:

Contraindication Category Examples of Conditions
Active Infections Sepsis, active tuberculosis, or other serious, uncontrolled infections. Treatment may be paused if a patient develops a significant infection.
Hypersensitivity A known history of severe allergic reaction or anaphylaxis to the active ingredient or any excipients in Aesim.
Specific Disease States Moderate-to-severe heart failure (Class III/IV), a history of multiple sclerosis or other demyelinating disorders, or certain blood disorders, depending on the drug’s specific mechanism.

Physicians must carefully weigh the risk-benefit profile, particularly for older patients and those with a history of recurrent infections or malignancy, as these groups may face an increased risk of adverse events.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Aesim (Simethicone) based on its non-systemic pharmacology. Since the active ingredient is not absorbed into the bloodstream, it is not associated with the majority of systemic drug interactions, including those mediated by metabolic enzyme systems (CYP interactions) or drug transporters. This results in no documented formal contraindications based on systemic drug interactions.

The single, officially documented clinically significant interaction falls under the category of Exposure-Modifying Interactions. This involves co-administration with Thyroid Preparations, such as Levothyroxine, where Simethicone can cause a reduction in the oral bioavailability of the thyroid hormone. This non-systemic effect is due to the physical binding or adsorption of the thyroid preparation within the gut lumen, which lessens its absorption.

To manage this interaction, regulatory bodies impose a Mandatory Administration Separation requirement. Specifically, the official prescribing information directs that Thyroid Preparations must be administered at least four hours before or after Aesim. No clinically significant interactions are documented for co-administration with alcohol, food, or common herbal supplements in the official regulatory labeling.

Mechanism of Action

Physical Mechanism: Reduction of Gastrointestinal Surface Tension

This domain describes Simethicone's primary mode of operation as a surface-active agent or surfactant. It does not interact with cellular receptors or enzymes; instead, it physically targets the high surface tension of the liquid film surrounding small, stable gas bubbles in the gastrointestinal (GI) lumen. This action initiates the mechanical cascade, causing the destabilization of the trapped gas foam and enabling gas transport.

️ Mechanistic Cascade: Luminal Gas Coalescence and Mobilization

This mechanism outlines the sequential physiological consequences of the surfactant action. By causing the small bubbles to rupture and coalesce into fewer, larger gas pockets, Simethicone transforms the physical state of the gas from a diffuse foam into a mobile form. This physical change supports the movement of gas from the GI tract via belching or flatus, resulting in a modulation of luminal pressure.

Constraint: Non-Systemic Action and Limitations

The drug's mechanism is defined by its non-systemic nature, restricting its action strictly to the contents of the GI lumen. This means the mechanism can only modulate gas that is present as a foam within the digestive tract; its action does not extend to gas absorbed into the bloodstream or gas that is structurally contained in solid intestinal matter.

Dosage and Administration Information

How to Use Aesim

Aesim is administered exclusively by the oral route and is available in various dosage forms, including softgel capsules, chewable tablets, and oral suspension. The general principle of its use is defined by the timing of its administration relative to meals.

Standard adult dosing for individuals 12 years and older typically ranges from 40 mg to 125 mg per dose. The medicine is taken after meals and again at bedtime, but can also be used on an as-needed basis. In a 24-hour period, the total intake must not exceed the maximum allowed self-medication limit of 500 mg.

Proper administration requires specific steps based on the form. Chewable tablets must be thoroughly chewed. The liquid suspension must be shaken well and precisely measured using only the provided dropper or syringe. Furthermore, population-specific adjustments are mandatory for children and infants, with defined lower doses (e.g., 20 mg for infants) that reflect specific age groups. If a dose is missed, standard instructions advise taking it as soon as possible, but strictly prohibit taking a double dose to compensate. This structured approach ensures use is consistent with established guidelines.

Recent Clinical Evidence

Aesim: Recent Clinical Evidence

Overview of Studies

Research reports findings that suggest the compound was evaluated for short-term use in adults with mild-to-moderate joint pain. The key Phase III trial reported that participants receiving the compound showed changes in measured scores compared to the placebo group. The research examined whether the compound impacted inflammatory markers commonly associated with the condition.

Research examined the timeline of observed effects, with some measured effects observed within 30 minutes of administration. The study compared outcomes against rapid-action alternatives evaluated within the research.

Mechanism of Action and Tolerability

Research hypothesizes that the active ingredient may influence specific pain receptors. The analysis primarily focused on the pharmacokinetic properties of the compound.

In the study, the compound was reported to be well tolerated. Researchers advised participants to administer the compound with food, and researchers evaluated the incidence of gastrointestinal side effects. Co-administration with other common non-steroidal anti-inflammatory drugs (NSAIDs) was examined in safety studies.

Study Limitations and Scope

Studies excluded participants with kidney issues, and one preliminary finding suggested a potential for interaction with pre-existing conditions. Further small-scale studies suggested that some participants reported continued change over a 12-week course of treatment. The FDA approved the compound for its specified indication, following regulatory review of the evidence.

Key Studies & References Long-term Safety and Tolerability Profile of Aesim: Findings from a 12-Week Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Aesim (FAQ)

Q: What is Aesim and how does it work?

A: Aesim is a type of medicine known as an anti-inflammatory analgesic or a non-steroidal anti-inflammatory drug (NSAID). Its active ingredient is mefenamic acid.

It works by stopping the body from making substances called prostaglandins. Prostaglandins are natural chemicals released in the body that cause inflammation, pain, and fever. By blocking these substances, Aesim helps reduce pain and swelling.

Q: What is Aesim used for?

A: Aesim is typically used for the short-term relief of mild to moderate pain from various conditions, including:

  • Muscle and joint injuries
  • Dental pain
  • Post-surgery pain
  • Pain after childbirth
  • Menstrual pain (dysmenorrhea)

It can also be used to treat fever in some cases.

Q: Who should not take Aesim?

Do not take Aesim if you have:

  • A known allergy or severe reaction to mefenamic acid, aspirin, or other NSAIDs.
  • A history of asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs.
  • A current or recent history of stomach or intestinal bleeding or ulcers.
  • Severe kidney or liver disease.
  • Severe heart failure.
  • You are currently in the last three months of pregnancy.
  • You are about to have, or recently had, coronary artery bypass graft (CABG) surgery.

Always discuss your full medical history with a healthcare professional before starting Aesim.

Q: What are the common side effects of Aesim?

A: Common side effects of Aesim can include:

  • Stomach problems such as upset stomach, nausea, or vomiting.
  • Abdominal pain or discomfort.
  • Diarrhea or constipation.
  • Heartburn.
  • Dizziness or headache.

If you experience severe abdominal pain, black or tarry stools, or vomit that looks like coffee grounds, stop taking Aesim and seek emergency medical help, as these can be signs of serious stomach bleeding.

Q: Can I take Aesim with other pain relievers?

A: Do not take Aesim with other NSAIDs or aspirin unless specifically directed by your healthcare provider. This combination can significantly increase your risk of serious side effects, such as stomach bleeding and ulcers.

It is generally safe to take Aesim with acetaminophen (Tylenol), as they belong to different classes of medication and work in different ways. However, you should still consult a healthcare provider or pharmacist before combining any medications.

How should Aesim be stored and disposed of?

Prescription drug storage must strictly follow the conditions specified in the official labeling to ensure the product’s identity, strength, and purity. This typically requires keeping the medication in the original container, away from children, and at a controlled temperature, which is often room temperature. Protection from light or moisture may also be required if stability studies indicate sensitivity.

For disposal, the primary method for unused or expired medicines is a drug take-back program or mail-back envelope. If these options are unavailable, check if the medicine is on the FDA flush list; if so, flush immediately. Otherwise, most medicines should be mixed with an undesirable substance (like dirt or coffee grounds), sealed in a bag, and discarded in the household trash. Always scratch out personal information on the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Aesim found in:

A-Z Index: